首站-论文投稿智能助手
典型文献
Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon α2b
文献摘要:
Recombinant human interferon α2b(rhIFNα2b)is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C.The current identification test for rhIFNα2b is complex.In this study,an anti-rhIFNα2b nanobody was discovered and used for the development of a rapid lateral flow strip for the identification of rhIFNα2b.RhIFNα2b was used to immunize an alpaca,which established a phage nanobody library.After five steps of enrichment,the nanobody I22,which specifically bound rhIFNα2b,was isolated and inserted into the prokaryotic expression vector pET28a.After subsequent purification,the physicochemical properties of the nanobody were determined.A semiquantitative detection and rapid identification assay of rhIFNα2b was developed using this novel nanobody.To develop a rapid test,the nanobody I22 was coupled with a colloidal gold to produce lateral-flow test strips.The developed rhIFNα2b detection assay had a limit of detection of 1 μg/mL.The isolation of I22 and successful construction of a lateral-flow immunochromatographic test strip demonstrated the feasibility of performing ligand-binding assays on a lateral-flow test strip using recombinant protein products.The principle of this novel assay is generally applicable for the rapid testing of other com-mercial products,with a great potential for routine use in detecting counterfeit recombinant protein products.
文献关键词:
作者姓名:
Xi Qin;Maoqin Duan;Dening Pei;Jian Lin;Lan Wang;Peng Zhou;Wenrong Yao;Ying Guo;Xiang Li;Lei Tao;Youxue Ding;Lan Liu;Yong Zhou;Chuncui Jia;Chunming Rao;Junzhi Wang
作者机构:
National Institutes for Food and Drug Control,Beijing,100050,China;Synthetic and Functional Biomolecules Center,Peking University,Beijing,100871,China;WHO Collaboration Centre for Biologicals Standardization and Evaluation,Beijing,100050,China
引用格式:
[1]Xi Qin;Maoqin Duan;Dening Pei;Jian Lin;Lan Wang;Peng Zhou;Wenrong Yao;Ying Guo;Xiang Li;Lei Tao;Youxue Ding;Lan Liu;Yong Zhou;Chuncui Jia;Chunming Rao;Junzhi Wang-.Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon α2b)[J].药物分析学报(英文),2022(02):308-316
A类:
RhIFN,alpaca,I22,counterfeit
B类:
Development,novel,nanobody,lateral,flow,immunochromatographic,rapid,detection,recombinant,human,interferon,2b,Recombinant,rhIFN,widely,used,antiviral,therapy,agent,treatment,hepatitis,current,identification,complex,In,this,study,was,discovered,development,immunize,which,established,phage,library,After,five,steps,enrichment,specifically,bound,isolated,inserted,into,prokaryotic,expression,vector,pET28a,subsequent,purification,physicochemical,properties,were,determined,semiquantitative,developed,using,To,coupled,colloidal,gold,produce,strips,had,limit,isolation,successful,construction,demonstrated,feasibility,performing,ligand,binding,assays,protein,products,principle,generally,applicable,testing,other,mercial,great,potential,routine,detecting
AB值:
0.428095
相似文献
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Duo Zuo;Yongzi Chen;Xinwei Zhang;Zhuozhi Wang;Wenna Jiang;Fan Tang;Runfen Cheng;Yi Sun;Lu Sun;Li Ren;Rui Liu-Department of Clinical Laboratory;Department of Tumor Cell Biology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Biomedical Engineering,Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer
Xu Zhang;Na Qin;Jingyi Fan;Chang Zhang;Qi Sun;Yayun Gu;Meng Zhu;Erbao Zhang;Juncheng Dai;Guangfu Jin;Hongxia Ma;Zhibin Hu;Hongbing Shen-Department of Epidemiology,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing 211166,China;Jiangsu Key Lab of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing 211166,China;Health Management Center,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School,Nanjing Medical University,Suzhou 215008,China;Research Units of Cohort Study on Cardiovascular Diseases and Cancers,Chinese Academy of Medical Sciences,Beijing 100730,China
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
Haoran Mu;Dongqing Zuo;Jie Chen;Zhigang Liu;Zhuo Wang;Liu Yang;Qihui Shi;Yingqi Hua-Shanghai Bone Tumor Institute and Department of Orthopedics,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Center for Systems Biomedicine,Shanghai Jiao Tong University,Shanghai 200240,China;Shanghai Key Laboratory of Medical Epigenetics and the International Co-laboratory of Medical Epigenetics and Metabolism(MOST),Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer(SMHC)and Institute of Fudan-Minhang Academic Health System,Minhang Hospital,Fudan University,Shanghai 201199,China;Shanghai Engineering Research Center of Biomedical Analysis Reagents,Shanghai 201203,China
Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays
Jin-ping Pang;Chao Shen;Wen-fang Zhou;Yun-xia Wang;Lu-hu Shan;Xin Chai;Ying Shao;Xue-ping Hu;Feng Zhu;Dan-yan Zhu;Li Xiao;Lei Xu;Xiao-hong Xu;Dan Li;Ting-jun Hou-Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences,Cancer Hospital of University of Chinese Academy of Sciences,Zhejiang Cancer Hospital,Hangzhou 310022,China;School of Life Science,Huzhou University,Huzhou 313000,China;Institute of Bioinformatics and Medical Engineering,School of Electrical and Information Engineering,Jiangsu University of Technology,Changzhou 213001,China;State Key Lab of CAD&CG,Zhejiang University,Hangzhou 310058,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。